feburic治疗痛风患者效果好吗？

Gout is a common and complex type of arthritis. People of all ages may suffer from gout. Gout patients often experience sudden joint pain at night. The pain is quite high and feels like a big toe being burned. If not treated in time, the consequences of delay will be that the pain will become stronger and more unbearable. And it can also endanger other normal functions of the body. feburic (febuxostat, febuxostat) is an anti-gout drug. Because feburic (febuxostat, febuxostat) has a significant inhibitory effect on both oxidized and reduced XOR, feburic (febuxostat, febuxostat) has a more powerful and long-lasting effect in reducing uric acid. Therefore, feburic (febuxostat, febuxostat) can be used to treat chronic hyperuricemia in gout. On September 4, 2018, the domestic CFDA officially approved the listing of feburic (febuxostat, febuxostat).  

feburic (febuxostat, febuxostat) is a new non-purine xanthine oxidase (XO) selective inhibitor that works by reducing blood urate concentration. It is fully absorbed orally and has a high utilization rate. Food and antacids have no significant effect on its absorption. Unlike allopurinol, its structure is a non-purine analogue, so it is selective in inhibiting xanthine oxidase and has little effect on other enzymes in purine or pyrimidine metabolism. That is to say, feburic (febuxostat, febuxostat) is less likely to be affected by other factors and has a stable effect.

A phase III clinical trial compared the efficacy of feburic (80 and 120 mg/d) with allopurinol (300 mg/d) in parallel. A 1-year study of 760 patients showed that compared with the allopurinol group, more patients in the feburic (febuxostat, febuxostat) group achieved the main trial efficacy indicator - the sUA concentration was measured below 60 mg/L in the last 3 months (all subjects were gout patients, and the pre-trial sUA concentrations were all above 80 mg/L); after 52 weeks of treatment, feburic (febuxostat, febuxostat) failed Significantly reduced the area of tophi (tophi is an aggregate of urate crystals unique to gout), but this effect was more obvious in the high-dose group early in the trial; in each treatment group, patients with sUA concentration (<60 mg/L) were less likely to have gout attacks, and their tophi area was more significantly reduced; adverse reactions and their incidence rates were similar in each treatment group, including abnormal liver function, diarrhea, headache, joint-related signs and symptoms, and musculoskeletal/connective tissue symptoms.